ストックスクリーナーアプリを入手
32.75
0.79%
-0.26
前日終値:
$33.01
開ける：
$32.8
24時間の取引高:
998.70K
Relative Volume:
1.05
時価総額：
$1.95B
収益：
-
当期純損益:
$-131.11M
株価収益率:
-15.06
EPS:
-2.1745
ネットキャッシュフロー:
$-102.47M
1週間 パフォーマンス:
+6.96%
1か月 パフォーマンス:
+28.84%
6か月 パフォーマンス:
+11.74%
1年 パフォーマンス:
+219.82%
1日の値動き範囲:
$31.09
$33.27
1週間の範囲:
$30.01
$33.27
52週間の値動き範囲:
$9.96
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Compare TYRA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
32.75 | 1.95B | 0 | -131.11M | -102.47M | -2.1745 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-15 | 開始されました | Guggenheim | Buy |
| 2026-04-06 | 開始されました | Canaccord Genuity | Buy |
| 2026-02-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-02-10 | 開始されました | William Blair | Outperform |
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-05-21 | 再開されました | Piper Sandler | Overweight |
| 2025-01-07 | 開始されました | UBS | Buy |
| 2024-10-18 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-08-15 | 開始されました | Piper Sandler | Overweight |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-06-30 | 開始されました | Wedbush | Outperform |
| 2023-02-03 | 開始されました | Oppenheimer | Outperform |
| 2022-06-23 | 開始されました | H.C. Wainwright | Buy |
| 2022-03-08 | アップグレード | Jefferies | Hold → Buy |
| 2021-11-08 | ダウングレード | Jefferies | Buy → Hold |
| 2021-10-11 | 開始されました | BofA Securities | Buy |
| 2021-10-11 | 開始されました | Cowen | Outperform |
| 2021-10-11 | 開始されました | Jefferies | Buy |
すべてを表示
Tyra Biosciences Inc (TYRA) 最新ニュース
Behavioral Patterns of TYRA and Institutional Flows - Stock Traders Daily
Enterprise value to EBIT forward of Tyra Biosciences, Inc. – BOATS:TYRA - TradingView
Price to sales forward of Tyra Biosciences, Inc. – BOATS:TYRA - TradingView
Wolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendation - MSN
Enterprise value to EBITDA forward of Tyra Biosciences, Inc. – NASDAQ:TYRA - TradingView
Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data? - Insider Monkey
Bladder Cancer Pipeline Expands as 80+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2500 Growth Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2000 Growth Benchmark - marketscreener.com
(TYRA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Tyra Biosciences, Inc.(NasdaqGS:TYRA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 3000E Growth Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell Microcap Index - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell 2500 Value Benchmark - marketscreener.com
10 Most Promising Cancer Stocks According to Wall Street Analysts - Insider Monkey
Tyra Biosciences, Inc.(NasdaqGS:TYRA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Form 144 TYRA BIOSCIENCES For: 26 June By Investing.com - Investing.com Nigeria
Form 144 | TYRA BIOSCIENCES, INC.(TYRA.US) Insider Proposes to Sell 9.54 Million in Common Stocks - Moomoo
TYRA (NASDAQ: TYRA) sells common shares under Rule 144 in June 2026 - Stock Titan
Tyra Bioscience, Inc Actuals & Estimates (NASDAQ:TYRA) - TradingView
Tyra Biosciences (TYRA) Gains Attention On Phase II Results, Is The Upside Already Priced In? - Sahm
TYRA Forecast — Price Target — Prediction for 2027 - TradingView
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
JonesTrading Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $56 - 富途牛牛
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42 - 富途牛牛
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight - Yahoo Finance
Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tyra Biosciences (TYRA) Slips 2.58%: Support Level in Focus After Weekly DeclineReversal Trade - dars.gov.et
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Analysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), Tyra Bioscience (TYRA) - The Globe and Mail
Tyra Biosciences Inc (TYRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tyra Biosciences Inc (TYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tyra Biosciences Inc (TYRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tyra Biosciences Inc (TYRA) Institutional Confidence - TradingKey
Tyra Biosciences Inc (TYRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tyra Biosciences Inc (TYRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tyra Biosciences Inc (TYRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
TYRA PE Ratio & Valuation, Is TYRA Overvalued - Intellectia AI
TYRA Initiated Coverage by Jones Trading -- Rating Set to Buy - GuruFocus
Wedbush Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $53 - Moomoo
TYRA Q1 2026 Earnings: EPS Miss Amid Pre-Revenue Stage, Stock Gains 5.55%Earnings Seasonality - newsline.com
Tyra Biosciences (TYRA) Surges 5.55% on Strong Volume, Testing Key Resistance LevelsCash Flow Strong Stocks - newsline.com
Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism? - Yahoo Finance
Urothelial Carcinoma Market on Track for Major Expansion - openPR.com
Urothelial Carcinoma Market on Track for Major Expansion by 2036, According to DelveInsight | Bristol-Myers Squibb, Astellas Pharma, Pfizer, Johnson & Johnson, Pfizer, Tyra Biosciences, Infinity - Barchart.com
Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says - Moomoo
TYRA Maintains Rating by B of A Securities -- Price Target Raised to $42 - GuruFocus
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.8, Implies 96% Upside - TradingView
BofA Securities Raises Price Target on Devon Energy to $42 From $37, Buy Rating Kept - marketscreener.com
Tyra Biosciences Inc (TYRA) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):